These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5461337)

  • 1. Prolonged low-dosage administration of hexamethylmelamine (NC 13875).
    Wilson WL; Bisel HF; Cole D; Rochlin D; Ramirez G; Madden R
    Cancer; 1970 Mar; 25(3):568-70. PubMed ID: 5461337
    [No Abstract]   [Full Text] [Related]  

  • 2. Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.
    Wampler GL; Mellette SJ; Kuperminc M; Regelson W
    Cancer Chemother Rep; 1972 Aug; 56(4):505-14. PubMed ID: 5081594
    [No Abstract]   [Full Text] [Related]  

  • 3. [Do anabolic steroids protect bone marrow during cytostatic therapy?].
    Kopera H
    Med Klin; 1980 Jul; 75(15):539-43. PubMed ID: 7001201
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacology of antineoplastic agents in the elderly patient.
    Balducci L; Parker M; Sexton W; Tantranond P
    Semin Oncol; 1989 Feb; 16(1):76-84. PubMed ID: 2645652
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical pharmacology of hexamethylmelamine: Phase I study.
    Louis J; Louis NB; Linman JW; Donnelly WJ; Isaacs BL; Schwartz SO
    Clin Pharmacol Ther; 1967; 8(1):55-64. PubMed ID: 4959523
    [No Abstract]   [Full Text] [Related]  

  • 6. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
    Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
    Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
    Wiltshaw E; Kroner T
    Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of vomiting due to chemotherapy.
    Zulkhairi ; Kar AS
    Acta Med Indones; 2004; 36(4):219-26. PubMed ID: 15931721
    [No Abstract]   [Full Text] [Related]  

  • 9. [Side effect of antineoplastic agents and its prevention].
    Takemasa Y
    Naika; 1971 Oct; 28(4):685-9. PubMed ID: 4943167
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention and treatment of hemopoietic disorders during the chemotherapy of malignant ovarian tumors].
    Rybalka AM
    Pediatr Akus Ginekol; 1979; (5):45-6. PubMed ID: 503619
    [No Abstract]   [Full Text] [Related]  

  • 11. [Toxicity and inconveniences of chemotherapy].
    Gino GC
    Cancro; 1973; 26(4):223-30. PubMed ID: 4806178
    [No Abstract]   [Full Text] [Related]  

  • 12. Amsacrine (AMSA)--a clinical review.
    Louie AC; Issell BF
    J Clin Oncol; 1985 Apr; 3(4):562-92. PubMed ID: 3884748
    [No Abstract]   [Full Text] [Related]  

  • 13. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
    Kurzrock R
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):9-11. PubMed ID: 11033833
    [No Abstract]   [Full Text] [Related]  

  • 14. Preventing emesis in lung cancer patients.
    J Support Oncol; 2007 Feb; 5(2):79-80. PubMed ID: 17348365
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cytostatic agents and changes in the blood picture].
    Kliment V; Stefanovic J; Deák E; Ziak F; Podhorská O
    Bratisl Lek Listy; 1969 Jul; 52(1):63-6. PubMed ID: 5806836
    [No Abstract]   [Full Text] [Related]  

  • 16. Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials.
    Carbone PP
    Cancer Chemother Rep 3; 1972 May; 3(1):73-5. PubMed ID: 4559007
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
    Ribaud P; Gouveia J; Misset JL; Mathé G
    Oncology; 1986; 43(2):78-82. PubMed ID: 3951788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences with cytostatic combination therapy in hormone-resistant metastasizing breast cancer].
    Brunner KW
    Schweiz Med Wochenschr; 1969 Sep; 99(36):1298-303. PubMed ID: 5351150
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerance of Navelbine in phase I-II clinical studies.
    Besenval M; Delgado M; Demarez JP; Krikorian A
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):37-40. PubMed ID: 2540533
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Kardinal CG; Luce JK
    Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.